FERMENTALG (ALGAE.PA)

EUR 0.4

(-3.59%)

EBITDA Summary of FERMENTALG

  • FERMENTALG's latest annual EBITDA in 2023 was -10.51 Million EUR , down -45.43% from previous year.
  • FERMENTALG's latest quarterly EBITDA in 2024 Q2 was -2.01 Million EUR , down 0.0% from previous quarter.
  • FERMENTALG reported an annual EBITDA of -6.88 Million EUR in 2022, up 16.6% from previous year.
  • FERMENTALG reported an annual EBITDA of -8.06 Million EUR in 2021, down -6.73% from previous year.
  • FERMENTALG reported a quarterly EBITDA of -2.01 Million EUR for 2024 Q1, up 26.42% from previous quarter.
  • FERMENTALG reported a quarterly EBITDA of -2.73 Million EUR for 2023 Q4, down 0.0% from previous quarter.

Annual EBITDA Chart of FERMENTALG (2023 - 2019)

Historical Annual EBITDA of FERMENTALG (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -10.51 Million EUR -45.43%
2022 -6.88 Million EUR 16.6%
2021 -8.06 Million EUR -6.73%
2020 -4.83 Million EUR 44.52%
2019 -6.32 Million EUR 0.0%

Peer EBITDA Comparison of FERMENTALG

Name EBITDA EBITDA Difference
Nicox S.A. -16.23 Million EUR 35.275%
European Medical Solutions 59 Thousand EUR 17913.559%
argenx SE -199.5 Million EUR 94.732%
BioSenic S.A. -6.79 Million EUR -54.65%
Celyad Oncology SA -7.76 Million EUR -35.386%
Hyloris Pharmaceuticals SA -14.98 Million EUR 29.84%
Onward Medical N.V. -35.23 Million EUR 70.171%
Oxurion NV -16.72 Million EUR 37.175%
PHAXIAM Therapeutics S.A. -22.93 Million EUR 54.165%
Financière de Tubize SA 184.57 Thousand EUR 5794.286%
UCB SA 1.26 Billion EUR 100.828%